官方APP下载:英语学习播客(支持苹果手机、安卓手机)
创办于2003年
UNSV记不住?那就记中文谐音“忧安思危”吧!
  Slow and Steady Wins the Race!
UNSV英语学习频道 - Slow and steady wins the race!
公众微信服务号(英语全能特训)
英语全能特训(微信公众服务号)
UNSV英语学习频道淘宝网店
客服短信:18913948480
客服邮箱:web@unsv.com
初级VIP会员
全站英语学习资料下载。
¥98元/12个月

US Expected to Approve Pfizer Vaccine for Teens

作者:Bryan Lynn 发布日期:5-5-2021

The United States is expected to approve the use of Pfizer's COVID-19 vaccine for young people aged 12 to 15 by next week.

A federal official told The Associated Press that the Food and Drug Administration (FDA) plans to expand its emergency use authorization for Pfizer's vaccine to the new age group.

The official did not want to be identified because there has been no public announcement about Pfizer's vaccine plans. The New York Times first reported on the expected timing of the plan.

The official said the approval is expected to come by early next week. The person added that the FDA also plans to approve Pfizer's two-shot vaccine for even younger children later this year.

The FDA's expansion of its emergency use authorization is the first step in the approval process. That action would be followed by a meeting of a federal vaccine advisory committee to discuss whether to recommend the injection for 12- to 15-year-olds.

If the Centers for Disease Control and Prevention approves the committee's recommendation, the shots could begin. Those steps could be completed in a matter of days.

In March, Pfizer released the first results from a vaccine study involving 2,260 U.S. volunteers aged 12 to 15. The study showed there were no cases of COVID-19 among fully vaccinated individuals compared with 18 in the group who were given a placebo, a shot of inactive substance.

The 12- to 15-year-olds had side effects similar to young adults, Pfizer said. The main side effects are pain, increased temperature, tiredness and chills, especially after the second shot. The study will continue to follow test subjects for two years to gain more information about long-term protection and safety.

Pfizer is not the only company seeking to lower the age limit for its vaccine. Results are also expected by the middle of this year from a U.S. study of Moderna's vaccine in 12- to 17-year-olds.

The FDA is permitting both companies to also begin U.S. studies in children 11 and younger.

More than 131 million doses of Pfizer's vaccine have already been given in the U.S., where demand for vaccines among adults has greatly slowed in recent weeks.

Younger people generally have a much lower risk of experiencing serious side effects from COVID-19. But they started making up a larger share of new U.S. cases as an increasing number of adults got vaccinated and some virus-related restrictions were eased.

Officials hope that expanding the vaccines to young people will help efforts to safely reopen schools in the autumn.

The U.S. has ordered at least 300 million doses of the Pfizer shot by the end of July, enough to protect 150 million people.

I'm Bryan Lynn.

The Associated Press reported on this story. Bryan Lynn adapted the report for VOA Learning English. Hai Do was the editor.

We want to hear from you. Write to us in the Comments section, and visit our Facebook page.

Words in This Story

authorizev. to give permission for something to happen

recommend v. to suggest or propose

placebon. a harmless pill or medicine used as a control in testing new drugs

chills n. a feeling of cold

dose – n. the amount of a medicine, drug, or vitamin that is taken at one time

版权所有©2003-2019 南京通享科技有限公司,保留所有权利。未经书面许可,严禁转载本站内容,违者追究法律责任。 互联网经营ICP证:苏B2-20120186
网站备案:苏公网安备 32010202011039号苏ICP备05000269号-1中国工业和信息化部网站备案查询
广播台